Investment Thesis
Early-stage pharmaceutical company with fortress balance sheet ($281.5M cash, no debt) but no meaningful revenue and substantial operating losses. Strong financial position provides near-term runway, but lack of commercial traction and negative cash flow indicate company is pre-profitability with unclear path forward.
Strengths
- Exceptional balance sheet with $281.5M cash and negligible debt (0.00x D/E ratio)
- Excellent liquidity position (22.62x current ratio) with minimal capital intensity
- Manageable cash burn rate of $3.5M annually relative to cash reserves
Risks
- No meaningful revenue ($32K) with essentially zero top-line commercial traction
- Significant operating losses (-$25.9M) and negative cash flow (-$3.6M FCF) with no path to profitability visible
- Typical biotech execution risk: long development timelines, high failure rates, regulatory uncertainty, and extended runway requirements
Key Metrics to Watch
- Revenue growth trajectory and first meaningful commercial milestones
- Quarterly cash burn rate and projected cash runway in months
- Operating expense trends relative to R&D investment efficiency
Financial Metrics
Revenue
32.0K
Net Income
-23.7M
EPS (Diluted)
$-1.21
Free Cash Flow
-3.6M
Total Assets
312.3M
Cash
281.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-80,865.6%
Net Margin
-74,087.5%
ROE
-8.3%
ROA
-7.6%
FCF Margin
-11,256.3%
Balance Sheet & Liquidity
Current Ratio
22.62x
Quick Ratio
22.62x
Debt/Equity
0.00x
Debt/Assets
8.5%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T06:54:20.857490 |
Data as of: 2026-03-31 |
Powered by Claude AI